SAHA treatment reveals the link between histone lysine acetylation and proteome in nonsmall cell lung cancer A549 cells

Journal of Proteome Research

Volumn 12, Issue 9, 2013, Pages 4064-4073

  Wu, Quan ^a   Xu, Weiqing ^a   Cao, Lejie ^a   Li, Xin ^b   He, Tieming ^b   Wu, Zhiwei ^a   Li, Wenting ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Jingjie PTM BioLab (Hangzhou) Co Ltd   (China)

Author keywords

A549 cells; histone lysine acetylation; NSCLC; proteome; SAHA

Indexed keywords

HISTONE; HISTONE DEACETYLASE; LYSINE; MARKER; PROTEOME; STABLE ISOTOPE; VORINOSTAT;

ACETYLATION; ANIMAL CELL; ARTICLE; BIOCHEMISTRY; BIOINFORMATICS; BIOLOGICAL FUNCTIONS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; ENZYME REGULATION; HISTONE MODIFICATION; LUNG NON SMALL CELL CANCER; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEOMICS; QUANTITATIVE ANALYSIS;

ACETYLATION; AMINO ACID SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; EPIGENESIS, GENETIC; GENE ONTOLOGY; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; LYSINE; MOLECULAR SEQUENCE ANNOTATION; MOLECULAR SEQUENCE DATA; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOME;

EID: 84883750603     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr4004079     Document Type: Article

References (25)

1. Shahbazian, M. D.; Grunstein, M. Functions of site-specific histone acetylation and deacetylation Annu. Rev. Biochem. 2007, 76, 75-00
2. Wagner, J. M.; Hackanson, B.; Lubbert, M.; Jung, M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy Clin. Epigenet. 2010, 1, 117-36
3. Olsen, E. A.; Kim, Y. H.; Kuzel, T. M.; Pacheco, T. R.; Foss, F. M.; Parker, S.; Frankel, S. R.; Chen, C.; Ricker, J. L.; Arduino, J. M.; Duvic, M. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma J. Clin. Oncol. 2007, 25 (21) 3109-15
4. Hagelkruys, A.; Sawicka, A.; Rennmayr, M.; Seiser, C. The biology of HDAC in cancer: The nuclear and epigenetic components Handb. Exp. Pharmacol. 2011, 206, 13-37
5. Munster, P. N.; Thurn, K. T.; Thomas, S.; Raha, P.; Lacevic, M.; Miller, A.; Melisko, M.; Ismail-Khan, R.; Rugo, H.; Moasser, M.; Minton, S. E. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer Br. J. Cancer 2011, 104, 1828-35
6. Robertson, F. M.; Woodward, W. A.; Pickei, R.; Ye, Z.; Bornmann, W.; Pal, A.; Peng, Z.; Hall, C. S.; Cristofanilli, M. Suberoylanilide hydroxamic acid blocks selfrenewal and homotypic aggregation of inflammatory breast cancer spheroids Cancer 2010, 116 (11 Suppl) 2760-67
7. Desai, D.; Das, A.; Cohen, L.; El-Bayoumy, K.; Amin, S. Chemopreventive efficacy of suberoylanilide hydroxamic acid (SAHA) against 4-(methylnitrosamino) -1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice Anticancer Res. 2003, 23, 499-03
8. Komatsu, N.; Kawamata, N.; Takeuchi, S.; Yin, D.; Chien, W.; Miller, C. W.; Koeffler, H. P. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells Oncol. Rep. 2006, 15 (1) 187-91
9. Imre, G.; Gekeler, V.; Leja, A.; Beckers, T.; Boehm, M. Histone deacetylase inhibitors suppress the inducibility of nuclear factor kappa B by tumor necrosis factor-alpha receptor-1 down-regulation Cancer Res. 2006, 66, 5409-18
10. Minucci, S.; Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nat. Rev. Cancer 2006, 6, 38-51
11. Xu, W. S.; Parmigiani, R. B.; Marks, P. A. Histone deacetylase inhibitors: molecular mechanisms of action Oncogene 2007, 26, 5541-52
12. Dokmanovic, M.; Clarke, C.; Marks, P. A. Histone deacetylase inhibitors: overview and perspectives Mol. Cancer Res. 2007, 5, 981-89
13. Jones, D. R.; Moskaluk, C. A.; Gillenwater, H. H.; Petroni, G. R.; Burks, S. G.; Philips, J.; Rehm, P. K.; Olazagasti, J.; Kozower, B. D.; Bao, Y. Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer J. Thorac. Oncol. 2012, 7 (11) 1683-90
14. Dasari, A.; Gore, L.; Messersmith, W. A.; Diab, S.; Jimeno, A.; Weekes, C. D.; Lewis, K. D.; Drabkin, H. A.; Flaig, T. W.; Camidge, D. R. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer Invest. New Drugs 2013, 31 (1) 115-25
15. Lee, E. M.; Shin, S.; Cha, H. J.; Yoon, Y.; Bae, S.; Jung, J. H.; Lee, S. M.; Lee, S. J.; Park, I. C.; Jin, Y. W.; An, S. Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells Int. J. Mol. Med. 2009, 24 (1) 45-50
16. Ong, S. E.; Blagoev, B.; Kratchmarova, I.; Kristensen, D. B.; Steen, H.; Pandey, A.; Mann, M. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics Mol. Cell. Proteomics 2002, 1, 376-86
17. Shechter, D.; Dormann, H. L.; Allis, C. D.; Hake, S. B. Extraction, purification and analysis of histones Nat. Protoc. 2007, 2 (6) 1445-57
18. Strahl, B. D.; Allis, C. D. The language of covalent histone modifications Nature 2000, 403 (6765) 41-55
19. Kim, H. J.; Bae, S. C. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs Am. J. Transl. Res. 2011, 3 (2) 166-79
20. Giannini, G.; Cabri, W.; Fattorusso, C.; Rodriquez, M. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives Future Med. Chem. 2012, 4 (11) 1439-60
21. Rando, Q. J. Combinatorial complexity in chromatin structure and function: revisiting the histone code Curr. Opin. Genet. Dev. 2012, 22 (2) 148-55
22. Kimura, A.; Horikoshi, M. Tip60 acetylates six lysines of a specific class in core histones in vitro Genes Cells 1998, 3 (12) 789-00
23. Howe, L.; Auston, D.; Grant, P.; John, S.; Cook, R. G.; Workman, J. L.; Pillus, L. Histone H3 specific acetyltransferases are essential for cell cycle progression Genes Dev. 2001, 15 (23) 3144-54
24. Daujat, S.; Bauer, U. M.; Shah, V.; Turner, B.; Berger, S.; Kouzarides, T. Crosstalk between CARM1 methylation and CBP acetylation on histone H3 Curr. Biol. 2002, 12 (24) 2090-97
25. Caron, C.; Boyault, C.; Khochbin, S. Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability Bioessays 2005, 27 (4) 408-15